{"filings":[{"id":2079077,"accession_number":"0001434647-26-000067","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-08-05T20:13:22+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q2 2026 net revenue $39.7M, up 53% YoY; MIPLYFFA drives growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $39.7M, including $30.2M from MIPLYFFA; up from $25.9M in Q2 2025.","Net income $8.8M ($0.14 per share); adjusted net income $15.2M ($0.25 per share).","Cash, cash equivalents and investments $260.2M as of June 30, 2026.","14 MIPLYFFA prescription enrollment forms in Q2; total 184 since launch; 69% covered lives.","66 patients enrolled in Phase 3 DiSCOVER trial for celiprolol; EU MAA re-examination requested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888717,"accession_number":"0001434647-26-000041","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-06-05T20:19:10+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zevra shareholders elect directors, ratify auditor; board declassification fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Douglas W. Calder elected as Class II director with 25.8M for, 8.0M withheld (12.6M broker non-votes).","Corey Watton elected as Class II director with 29.9M for, 3.8M withheld (12.6M broker non-votes).","Ratification of Ernst & Young as auditor for FY 2026 approved: 45.9M for, 234.8K against, 144.6K abstain.","Proposal to declassify board failed; received 32.6M for vs. 1.1M against, needed >66-2/3% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92839,"accession_number":"0001434647-26-000029","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.","Completed $50M sale of SDX portfolio to Commave Therapeutics; prepaid $63.1M term loan, now debt-free.","Net income of $37.9M ($0.60 diluted) includes $43.3M one-time gain; adjusted net income $11.5M ($0.18 diluted).","Cash, equivalents and securities $236.8M as of March 31, 2026; no near-term capital market dependency.","Enrolled 62 patients in Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome; FDA meeting expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":36220000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104013,"accession_number":"0001434647-26-000015","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"Zevra sells SDX portfolio to Commave for $50M, settles lawsuit, repays $63M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $50M; $25M at signing, $20M within 10 business days, $5M after records delivery.","Litigation with Commave in Delaware Chancery dismissed with prejudice; both parties release all claims.","Repaid $63M term loan (incl. $3M PIK interest) in full, terminating Credit Agreement and all liens.","CEO Neil McFarlane highlights debt-free balance sheet and enhanced financial flexibility.","Commave receives worldwide royalty-free perpetual license to SDX patents retained by Zevra."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104012,"accession_number":"0001434647-26-000009","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.","FY 2025 net revenue $106.5M (MIPLYFFA $87.4M); net income $83.2M ($1.35 diluted EPS) vs. $(105.5)M loss in FY 2024.","MIPLYFFA: 24 new prescription enrollment forms in Q4; 52 in 2025; 161 since launch; EU MAA under EMA review, 120-day questions received.","Justin Renz appointed CFO effective March 9, 2026; base salary $520k, 45% target bonus, option grant of 300k shares vesting over 4 years.","Cash, cash equivalents and securities $238.9M at year-end; 56.9M common shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120289,"accession_number":"0001434647-25-000018","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zevra appoints Timothy Sangiovanni as interim CFO effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Sangiovanni named interim principal financial officer, effective January 1, 2026.","Sangiovanni currently serves as SVP Finance and Corporate Controller; joined company in 2015.","No change in compensation arrangements in connection with the appointment.","No information provided on predecessor's departure or timing of permanent CFO search."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120288,"accession_number":"0001434647-25-000015","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zevra appoints Alicia Secor to board; director Wendy Dixon retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Wendy Dixon resigned effective Dec 2, 2025; no disagreement with company operations.","Alicia Secor appointed to board as Class I director, term expiring at 2028 annual meeting.","Secor will serve on Compensation and Audit committees; compensation per director policy.","Secor brings 30+ years life sciences experience, including CEO roles at Atalanta and Juniper."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120287,"accession_number":"0001193125-25-289865","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.","Separation benefits: 12 months base salary, 40% annual bonus, COBRA, full equity vesting.","Company has initiated search for new CFO; Neil F. McFarlane thanked Clifton for his leadership.","Clifton played role in company's transition from development to commercial-stage rare disease firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120286,"accession_number":"0001434647-25-000009","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.","Net loss $(0.5)M or $(0.01) per share vs $(33.2)M or $(0.69) per share in Q3 2024.","MIPLYFFA prescription enrollment forms total 137 since launch; market access 66% of covered lives.","Cash and securities $230.4M as of Sep 30, 2025; company believes sufficient to fund operations.","Arimoclomol EMA application validated under review; celiprolol Phase 3 trial enrolled 44 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":72345000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136874,"accession_number":"0001628280-25-039883","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.","Closed sale of PRV for $150.0M on April 1, boosting cash to $217.7M as of June 30.","Non-cash impairment of OLPRUVA intangible assets $58.7M and inventory obsolescence $11.7M.","Adjusted net loss $(3.2)M ($(0.06)/share) excluding PRV sale and impairment charges.","MIPLYFFA launch: 7 new enrollment forms in Q2, total 129 since launch; market access 52%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":46282000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154102,"accession_number":"0001193125-25-130714","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zevra Therapeutics stockholders elect Dixon and Favorito as Class I directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wendy Dixon elected with 25.8M for (9.1M withheld); Tamara Favorito with 25.6M for (9.3M withheld). Broker non-votes ~9.65M.","Dissident Mangless failed to comply with Rule 14a-19 and bylaws; his nominees Mickle and Regan disregarded despite 9.2M and 8.4M votes.","Ratification of Ernst & Young as auditor passed: 43.8M for, 360k against, 382k abstain; no broker non-votes.","81.4% of outstanding shares (44.5M of 54.7M) were present or represented at the May 29, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154101,"accession_number":"0001437749-25-016452","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.","Net loss of $3.1M ($0.06 per share) vs. $16.6M loss ($0.40) in Q1 2024; operating expenses $22.8M.","Closed sale of Pediatric Rare Disease PRV for $150M gross; net proceeds $148.3M received Apr. 1, 2025.","Cash, equivalents and investments $68.7M at Mar 31; combined with PRV proceeds, pro-forma cash $217M.","MIPLYFFA: 13 new prescription enrollment forms in Q1 (122 total); market access 38% of covered lives."],"consensus_eps_estimate":0.0824,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":20401000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154100,"accession_number":"0001193125-25-073991","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["2.01","2.02","8.01","9.01"],"status":"ready","headline":"Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.","PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.","Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.","Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172714,"accession_number":"0001437749-25-007032","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.","Entered asset purchase agreement to sell Rare Pediatric Disease PRV for $150M gross; expected net proceeds $148.3M.","Cash and investments $75.5M at Dec 31, 2024; with PRV sale, cash runway extends into 2029; no going concern disclosure.","MIPLYFFA commercial launch: 109 total prescription enrollment forms as of Dec 31; EU filing targeted H2 2025.","OLPRUVA added 4 new patients Q4; DiSCOVER trial (VEDS) enrolled 27 patients; strategic review for KP1077 ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172713,"accession_number":"0001193125-25-037619","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Zevra sells PRV for $150M cash; funds MIPLYFFA & OLPRUVA launches","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $150M, payable in cash at closing; expected within 30-45 days.","PRV granted in Sep 2024 upon FDA approval of MIPLYFFA for Niemann-Pick type C.","Transaction subject to HSR waiting period expiration; Cantor Fitzgerald advised.","CFO states non-dilutive capital strengthens balance sheet, supports commercial launches and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189734,"accession_number":"0001437749-24-036876","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.","Sven Guenther, Ph.D., Chief Scientific Officer, departing Zevra effective Dec. 23, 2024.","Development and scientific functions consolidated under Chief Medical Officer Adrian Quartel, M.D.","In-house drug discovery discontinued; laboratory facilities in Iowa and Virginia to close.","Changes include elimination of positions in CMC and Clinical Development as part of strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189733,"accession_number":"0001437749-24-035988","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.","Early adoption exceeded expectations; launch within 8–12 weeks post-approval as previously guided.","Indicated in combination with miglustat for neurological NPC in patients aged 2+.","AmplifyAssist patient support program launched to address insurance and access barriers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189732,"accession_number":"0001437749-24-034565","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.","FDA approved MIPLYFFA (arimoclomol) on Sept. 20 for Niemann-Pick type C; first-ever NPC drug approved.","Cash, equivalents, and investments $95.5M as of Sept. 30; cash runway forecast into 2027, excluding PRV sale.","Completed $64.5M public offering of 10.6M shares at $6.50; closed Iowa/Virginia labs, outsources early R&D.","OLPRUVA revenue minimal; 90 prescription enrollment forms for MIPLYFFA received by Oct. 31, 30% approved for reimbursement."],"consensus_eps_estimate":-0.0357,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":11569000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206243,"accession_number":"0001437749-24-029747","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra Therapeutics' MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease type C","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved MIPLYFFA (arimoclomol) for NPC in adult and pediatric patients 2 years+; first FDA-approved NPC treatment.","MIPLYFFA is indicated for use in combination with miglustat for neurological manifestations of NPC.","Zevra received a rare pediatric disease priority review voucher (PRV) with the approval.","Launch of AmplifyAssist patient support program; MIPLYFFA expected commercially available in 8-12 weeks.","Conference call and webcast on Sept 23, 2024 at 8 a.m. ET to discuss approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206242,"accession_number":"0001437749-24-026397","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.","FDA advisory committee voted arimoclomol effective for NPC; PDUFA target action date Sept 21, 2024.","Pro-forma cash $113.8M after $64.5M net from August public offering; cash runway into Q1 2027.","OLPRUVA added 9 new patient enrollments in Q2; reimbursement coverage expanded to 75% of covered lives.","Refinanced debt with $100M credit facility from Perceptive Advisors and HCR; initial draw $60M."],"consensus_eps_estimate":1.5278,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":7874000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206241,"accession_number":"0001193125-24-197943","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.","Net proceeds estimated at $56.1M after underwriting discounts and offering expenses.","Proceeds to fund pre-commercial launch of arimoclomol, OLPRUVA support, and development of celiprolol and KP1077.","Company believes net proceeds plus existing cash will fund operations through Q1 2026; closing expected Aug 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206240,"accession_number":"0001193125-24-196961","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.","Net loss for Q2 2024 estimated at $18.9M to $19.8M, compared to a $2.6M net loss in the prior-year quarter.","Preliminary diluted net loss per share ranges from ($0.47) to ($0.45), versus ($0.08) in Q2 2023.","Cash and cash equivalents as of June 30, 2024 were approximately $49.3 million.","The decrease in revenue is partially offset by reimbursements under AZSTARYS License Agreement and increased French expanded access program reimbursements."],"consensus_eps_estimate":1.5278,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":7874000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206239,"accession_number":"0001437749-24-024543","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA panel votes 11-5 that Zevra's arimoclomol is effective for NPC; PDUFA date Sep 21","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA GeMDAC voted 11 yes, 5 no that data support arimoclomol as effective for Niemann-Pick disease type C.","PDUFA action date for arimoclomol NDA is September 21, 2024.","The committee’s recommendation is non-binding but will be considered by the FDA.","Vote based on pivotal trial, long-term open-label extension, and expanded access program data.","Zevra CEO expresses confidence in arimoclomol's clinical benefit and path to approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206238,"accession_number":"0001437749-24-022668","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Zevra Therapeutics enters $75M at-the-market equity distribution agreement with Citizens JMP Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows sale of up to $75M in common stock at company's discretion.","Sales agent receives 3% commission on gross proceeds; shares sold under existing shelf registration.","Prior equity distribution agreement with Citizens JMP and RBC Capital terminated effective July 12, 2024.","Company is not obligated to make any sales under the new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206237,"accession_number":"0001437749-24-022362","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.","Meeting scheduled for August 2, 2024; background materials released two business days prior.","PDUFA action date for arimoclomol is September 21, 2024.","Arimoclomol is an orally delivered, first-in-class treatment for NPC, a rare genetic disease.","Zevra CEO highlights opportunity for NPC community to share treatment needs with the advisory committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223312,"accession_number":"0001437749-24-019074","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).","ESS decreased ~9 points after 5 weeks; at week 7: ESS -9.4 (QD), -8.8 (BID); IHSS -16.1 QD, -12.3 BID.","Sleep Inertia VAS decreased 25.9 (QD) and 17.2 (BID); Brain Fog Scale decreased 23.8 (QD) and 22.3 (BID).","PK data supports nighttime dosing; European Commission granted Orphan Drug Designation for KP1077 in IH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223311,"accession_number":"0001437749-24-016275","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zevra Therapeutics shareholders reject amendments to 2014 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class III directors elected: Thomas D. Anderson, Neil F. McFarlane, Alvin Shih, M.D.","Shareholders ratified Ernst & Young LLP as independent auditor for FY2024.","Advisory say-on-pay vote approved (11.2M for, 9.9M against).","Proposal to amend 2014 Equity Incentive Plan failed: 4.1M for, 17.0M against, 9.9M broker non-votes.","Approximately 74.5% of shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223310,"accession_number":"0001437749-24-015210","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.","Revenue $3.4M, including $2.2M French arimoclomol EAP reimbursement and $1.2M AZSTARYS royalties.","OLPRUVA commercial launch: 4 patient enrollments, ~75% covered lives as of May 1, 2024.","Arimoclomol NDA PDUFA date set for September 21, 2024; KP1077 positive Phase 2 IH data.","Debt refinancing with up to $100M; $60M drawn, net $14M added to cash; runway extends into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3425000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223309,"accession_number":"0001437749-24-011571","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["1.01","1.02","2.03","7.01"],"status":"ready","headline":"Zevra Therapeutics closes $100M senior secured loan facility; repays prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Secured $100M loan; $60M funded, $20M available later, $20M contingent on FDA approval of arimoclomol for Niemann-Pick disease Type C.","Interest rate is 3-month SOFR plus 7.00% (floor 4.00%); steps down to 6.00% or 6.50% based on net product sales thresholds.","Proceeds refinanced Nantahala note (repaid April 8, 2024), pay fees, and fund Olpruva and arimoclomol development/commercialization.","Loan matures 5 years from April 5, 2024; prepayment premiums and final payment premium of 3% of initial principal apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242781,"accession_number":"0001437749-24-009849","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Zevra restates FY2021-22 financials due to warrant errors; FY2023 revenue $27.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2023 net revenue $13.2M (vs $2.2M); FY2023 net revenue $27.5M (vs $10.2M). Net loss FY2023 $46.0M.","Non-cash restatement: warrant liability misclassified; FY2022 net income to increase ~$14.8M; material weakness expected.","Acer acquisition completed Nov 2023; OLPRUVA launch underway; >70% commercial/government payor coverage.","KP1077 Phase 2 IH study met safety endpoint; clinically meaningful sleepiness improvement; Phase 3 planning.","Arimoclomol NDA PDUFA date Sept 21, 2024; FDA plans advisory committee. Cash $67.7M; runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242780,"accession_number":"0001437749-24-009476","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra reports positive Phase 2 top-line data for KP1077 in idiopathic hypersomnia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KP1077 showed clinically meaningful improvement in excessive daytime sleepiness on ESS, maintained through open-label and double-blind phases.","Improvements also observed in IHSS, Sleep Inertia VAS, and Brain Fog severity scale at end of both open-label and double-blind periods.","Drug was well-tolerated at all doses (up to 320 mg/day); most common AEs were insomnia, headache, anxiety, nausea, decreased appetite.","Company plans to request end-of-Phase 2 meeting with FDA for guidance on Phase 3 trial design.","Study enrolled 66 patients; 50 continued into double-blind phase; not powered for statistical significance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242779,"accession_number":"0001437749-24-006540","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zevra Therapeutics furnishes investor presentation for meetings; no specific new material disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released a presentation on March 5, 2024, for use in investor meetings.","Presentation furnished under Item 7.01 Regulation FD; not deemed filed or incorporated.","Exhibit 99.1 contains the presentation; no additional financial or operational details provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242778,"accession_number":"0001437749-24-006365","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA extends arimoclomol review; new PDUFA date Sept 21, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended review of arimoclomol NDA for Niemann-Pick disease type C; new PDUFA action date Sept 21, 2024 (was June 21, 2024).","FDA determined additional analyses submitted by Zevra constitute a Major Amendment, causing the extension.","FDA reaffirmed intent to present the resubmission at an advisory committee meeting to be scheduled.","CEO McFarlane notes NPC patient advocacy petition; early access program continues.","Zevra previously announced acceptance of NDA resubmission in early January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242777,"accession_number":"0001437749-24-005904","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zevra Therapeutics amends bylaws to address universal proxy rules and update stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended and restated bylaws effective February 22, 2024.","Amendments incorporate SEC universal proxy rules (Rule 14a-19) for director nominations.","Requires stockholders soliciting proxies to use a non-white proxy card.","Includes technical and conforming changes to reflect updates in Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242774,"accession_number":"0001437749-24-003003","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K/A","filed_at":"2024-02-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Zevra completes Acer acquisition; pro forma net loss $59.5M for 9-mo 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma net loss of $59.5M for nine months ended Sep 30, 2023; $80.7M for FY 2022.","Acer acquisition closed Nov 17, 2023; exchange ratio 0.1210 Zevra shares per Acer share plus CVR.","Pro forma shares outstanding ~37.8M; Zevra issued ~2.96M shares for Acer equity.","Zevra purchased Acer's SWK term loans ($18.2M) and Marathon convertible notes ($12.0M).","Bridge loan of $10M provided to Acer; $1.5M anniversary payment due to Relief Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242776,"accession_number":"0001437749-24-001909","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zevra Therapeutics appoints Alvin Shih, M.D. to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Alvin Shih appointed as Class III director effective January 20, 2024.","Shih has rare disease experience, former COO of Pfizer's Rare Disease Research Unit.","Initial option grant of 58,800 shares vesting over 3 years, annual retainer $40,000.","Shih will receive additional option of 39,200 shares annually while serving on board.","No family relationships or transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242775,"accession_number":"0001437749-24-000822","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts Zevra's NDA resubmission for arimoclomol (NPC); PDUFA date June 21, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA deems resubmission a Class II complete response with 6-month review; PDUFA date June 21, 2024.","FDA intends to present arimoclomol NDA for discussion at an advisory committee meeting.","Resubmission addresses previous CRL concerns with additional trial metrics, preferred analyses, and supporting studies.","Arimoclomol is an orally-delivered, first-in-class treatment for Niemann-Pick disease type C."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260159,"accession_number":"0001437749-23-035343","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zevra resubmits NDA for arimoclomol (NPC) to FDA on Dec 22, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledgment letter and PDUFA date expected within 30 days.","Resubmission classified as Class II; review targeted within six months.","Additional data includes non-clinical studies, natural history, real-world data, and 4-year open-label extension results.","Open-label extension data suggests arimoclomol reduces long-term NPC progression.","Arimoclomol evaluated in 21 studies across 600+ subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260158,"accession_number":"0001193125-23-280240","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["1.01","2.01","7.01","8.01","9.01"],"status":"ready","headline":"Zevra completes Acer acquisition; issues stock, CVRs, and $6M registered direct offering","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Acer closed Nov 17; Acer shareholders receive 0.1210 Zevra shares + one CVR per share.","CVRs entitle holders to up to $76M upon achieving OLPRUVA net sales milestones ($35M-$200M) and regulatory approvals.","Zevra raised ~$6M via registered direct offering of 1,382,489 shares + warrants at $4.34/unit; also issued 917,934 shares to cancel Acer warrant.","Prior to merger, Zevra purchased Acer senior secured debt for $28.5M in cash, stock, and notes.","OLPRUVA (FDA-approved for UCDs) adds commercial-stage asset; EDSIVO for vEDS in Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260157,"accession_number":"0001437749-23-030485","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Therapeutics Q3 net loss widens to $14M; arimoclomol NDA resubmission on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue flat at $2.9M; net loss ($0.40/share) vs ($0.19) in prior year.","Arimoclomol NDA resubmission for NPC on track by end of 2023; six-month FDA review expected if Type II.","Proposed Acer acquisition (OLPRUVA, EDSIVO) on track for Q4 close; Acer shareholder vote Nov 8, 2023.","Neil McFarlane named President and CEO effective Oct 10, 2023.","Cash $83.4M; cash runway into 2026 includes NDA resubmission and KP1077 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":14244000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260156,"accession_number":"0001437749-23-029312","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zevra/Acer merger supplement filed; shareholder lawsuits prompt additional disclosures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three stockholder lawsuits filed (S.D.N.Y. and D. Del.) alleging proxy omissions; demand letters received.","Acer voluntarily supplements proxy statement on Oct. 30 to address litigation risks, without admitting materiality.","Supplement adds details: no standstill provisions in confidentiality agreements, no officer/director employment offers from Zevra.","Updated financial analyses: DCF terminal growth rate of -80%; implied equity values $0.90-$2.71 (Plan 1) and $1.13-$3.63 (Plan 2).","Acer board continues to unanimously recommend stockholder vote 'FOR' the merger at Nov. 8 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260155,"accession_number":"0001437749-23-027993","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zevra Therapeutics appoints Neil F. McFarlane as CEO effective Oct 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil F. McFarlane named President and CEO, succeeding interim CEO Christal Mickle who remains Chief Development Officer.","McFarlane receives $700k base salary, 60% target bonus, 600k stock options, and 200k RSUs vesting over 4 years.","Relocation assistance of $350k provided; severance includes 1x salary (1.5x upon change in control).","Board member Joseph B. Saluri resigned effective immediately after McFarlane's appointment.","McFarlane brings 25+ years biopharma experience, most recently CEO of Adamas Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277449,"accession_number":"0001437749-23-024969","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zevra sets $10M AZSTARYS milestone for 2023; merger with Acer announced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Next AZSTARYS sales milestone is $10.0M; expected to be achieved in FY 2023 per current prescription trends.","Zevra announced merger with Acer Therapeutics; Acer will become a wholly owned subsidiary upon shareholder approval.","Zevra hosted a conference call on Aug 31, 2023 to provide supplemental information on the merger.","Employee communication from interim CEO Christal Mickle distributed to Acer staff on Aug 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277448,"accession_number":"0001193125-23-225486","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Zevra Therapeutics to acquire Acer Therapeutics in stock-and-CVR merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acer stockholders receive 0.120 Zevra shares per share plus one CVR; Zevra to issue ~2.96M shares.","CVR milestones include up to $34M tied to OLPRUVA net sales, plus payments for FDA approvals of OLPRUVA and EDSIVO.","Zevra provides $10M initial bridge loan at 12% to Acer; total facility up to $16.5M.","Zevra purchases Acer debt from Nantahala: ~$20.2M SWK loans and ~$15.1M Marathon convertible notes.","Acer pays $3M termination fee if it accepts superior proposal or breaches non-solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277447,"accession_number":"0001437749-23-023412","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 revenue $8.5M, net loss $5.1M; arimoclomol NDA resubmission on track for Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $8.5M in Q2 2023 vs $1.3M YoY, driven by $5M AZSTARYS milestone and royalties.","Net loss $5.1M ($0.15/share) vs $24.0M ($0.70) in Q2 2022; prior year included $17.7M acquired IPR&D charge.","Cash $87.4M as of June 30, 2023, supporting operations into 2026; $5M milestone received after quarter-end.","Pre-submission meeting with FDA for arimoclomol NDA completed; resubmission expected Q4 2023.","Phase 2 KP1077 IH trial enrolling; interim data expected Q3 2023; topline data H1 2024; narcolepsy IND opened."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":11349000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277446,"accession_number":"0001437749-23-022345","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zevra Therapeutics appoints Thomas Anderson to board; Matthew Plooster resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Anderson appointed Class III director effective August 7, 2023; term expires at 2024 annual meeting.","Anderson is CEO of SwanBio Therapeutics and former chief commercial strategy officer at Sage Therapeutics.","Anderson receives initial option for 58,800 shares vesting over 3 years and $40,000 annual retainer.","Matthew R. Plooster resigned from the board effective immediately upon Anderson's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295368,"accession_number":"0001437749-23-014570","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Zevra Therapeutics CEO resigns; Q1 net loss widens to $11.8M, revenue $2.9M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Richard W. Pascoe resigns effective June 1, 2023; Chief Development Officer Christal Mickle appointed interim CEO.","Q1 net loss of $11.8M ($0.34 per share) vs $1.9M loss a year ago; revenue fell to $2.9M from $4.0M.","Cash and investments $95.3M; expects operating runway into 2026, funding arimoclomol NDA resubmission and KP1077 program.","Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023; KP1077 Phase 2 IH interim data expected Q3 2023.","Share repurchases of 665,739 shares for ~$3.4M during Q1; $39.1M remaining under program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295367,"accession_number":"0001437749-23-012904","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zevra CEO Richard Pascoe resigns effective June 1, 2023; two directors not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Richard Pascoe resigned effective June 1, 2023; transition agreement provides 12 months base salary, pro-rated bonus, extended option exercise period.","Directors Matthew Plooster and Joseph Saluri will not stand for re-election at 2024 annual meeting; will resign once board finds replacements.","Board to immediately search for director candidates to fill the pending vacancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295366,"accession_number":"0001437749-23-011154","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zevra Therapeutics dissident slate wins board seats; three new directors elected","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mangless-nominated directors Bode, Calder, Watton elected; company nominees Pascoe, Posner, Tierney received 3.3M, 2.7M, and 2.5M for votes vs 14.2M, 14.8M, and 15.0M withheld.","Ratification of Ernst & Young as auditor approved with 16.3M for vs 0.3M against and 0.9M abstentions.","Mangless Proposal to repeal bylaw changes adopted after Jan 1, 2023 passed (14.5M for, 2.9M against); no such changes existed, so it had no effect.","Turnout: 50.73% of outstanding shares (17.5M of 34.5M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315910,"accession_number":"0001437749-23-008527","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zevra Therapeutics appoints Wendy L. Dixon, Ph.D. to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Dixon appointed effective after April 25, 2023 annual meeting, filling vacancy from Dr. Travis Mickle's resignation.","She will serve as Class I director with term expiring at 2025 annual meeting.","Initial option grant of 22,500 shares vesting over three years; annual retainer of $40,000.","Dr. Dixon has over 40 years biopharma experience, previously CMO at Bristol Myers Squibb and SVP at Merck.","No family relationships or reportable transactions under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-30T23:59:59+00:00|315910"}